Sedative-Hypnotics

Key Points

• Sedative-hypnotics are CNS depressants prescribed for insomnia — use only when nonpharmacologic measures have failed
• Benzodiazepines are first-generation hypnotics — significant dependence potential; Schedule IV; taper on discontinuation
• Z-drugs (zolpidem, eszopiclone, zaleplon) — nonbenzodiazepine GABA-A agonists; Schedule IV; similar abuse risk
• Z-drugs + Beers Criteria: Avoid in older adults (high fall risk, confusion, anterograde amnesia)
• Ramelteon: Melatonin receptor agonist — not a controlled substance; no addiction risk; preferred in older adults
• Allow 7–8 hours of sleep time after taking Z-drugs or benzodiazepines to prevent next-day sedation impairment

Drug Class Overview

Sedative-hypnotics are CNS depressants that produce sleep. The distinction between sedatives (anxiolytics) and hypnotics is primarily dose-dependent — low doses cause anxiolysis and sedation; higher doses induce sleep. Insomnia disorder is defined as significant inability to initiate or maintain sleep ≥3 nights/week for ≥1 month, leading to daytime impairment.

Nonpharmacologic measures must be attempted first: Sleep hygiene, cognitive behavioral therapy for insomnia (CBT-I), stimulus control, and relaxation techniques.

Major Drug Classes

Benzodiazepines

Mechanism: Enhance GABA-A receptor activity → increased chloride conductance → CNS depression → sedation and sleep induction.

Schedule: DEA Schedule IV — physical dependence and abuse potential.

Agents: Temazepam (drug of choice for older adults with hepatic disease), triazolam (rapid onset — take while in bed; contraindicated in cirrhosis), midazolam (IV; short-acting procedural sedation).

Adverse Effects: Daytime sedation, anterograde amnesia, confusion, rebound insomnia on discontinuation, physical dependence.

Key Rule: Never discontinue abruptly — taper to prevent withdrawal seizures and rebound insomnia.

Nonbenzodiazepine Z-Drugs (GABA-A Agonists)

Nonbenzodiazepines act on GABA-A receptors but at different subunits than classic benzodiazepines → less anxiolytic effect; more selective for sleep induction.

Drug	Duration	Key Notes
Zolpidem (Ambien)	Short-acting	Most prescribed; sleep initiation; take immediately before bed; 7-hour sleep window required
Zaleplon (Sonata)	Ultra-short	7–10 day max; only decreases sleep latency (no effect on total sleep time or awakenings)
Eszopiclone (Lunesta)	Long-acting	Only Z-drug approved for long-term use (12+ months); reduces sleep latency and increases total sleep time; unpleasant taste common

Shared Adverse Effects: Anterograde amnesia, complex sleep behaviors (sleep-walking, sleep-driving — perform without awareness), hallucinations, worsening depression and suicidal ideation.

Z-Drug Complex Sleep Behaviors — FDA Warning

Zolpidem, zaleplon, and eszopiclone are associated with complex sleep behaviors including sleepwalking, sleep-driving, and other activities performed while not fully awake. These behaviors may result in serious injury or death. Discontinue if patient experiences complex sleep behavior.

Food Interaction: Do NOT take with high-fat meals — delays onset by up to 1 hour.

Beers Criteria: Z-drugs are on the Beers Criteria for Potentially Inappropriate Medications in Older Adults — avoid due to increased risk of falls, fractures, and cognitive impairment.

Melatonin Receptor Agonists

Ramelteon (Rozerem): Selective melatonin MT1/MT2 receptor agonist → mimics natural melatonin → sleep onset facilitation.

Advantages: Not a controlled substance; no dependence potential; no rebound insomnia; appropriate for long-term use and in older adults.

Primary Effect: Reduces sleep latency (decreases time to fall asleep); no significant effect on total sleep time.

Adverse Effects: Dizziness, headache, somnolence, endocrine effects (prolactin elevation, testosterone reduction with long-term use).

Contraindication: Severe hepatic impairment. Caution in depression and sleep apnea. Do not take with high-fat meals.

Orexin Receptor Antagonists

Agents: Suvorexant (Belsomra), lemborexant (Dayvigo), daridorexant (Quviviq) — all Schedule IV.

Mechanism: Block orexin (hypocretin) receptors → suppress wakefulness drive → facilitate sleep onset and maintenance.

Advantage over benzodiazepines: Less respiratory depression, potentially lower dependence potential.

Administration: Must be in bed within 30 minutes of taking; allow 7 hours sleep time.

Adverse Effects: Daytime somnolence, sleep paralysis, hypnagogic hallucinations.

Nursing Assessment

Before Administration:

• Assess sleep patterns: sleep latency, duration, nighttime awakenings, daytime impairment
• Evaluate nonpharmacologic sleep strategies already attempted
• Review current medications for CNS depressant interactions (opioids, alcohol, benzodiazepines)
• Fall risk assessment — implement bed alarm and call light instructions for all hypnotics
• Older adults: Beers Criteria — consider ramelteon or melatonin instead of benzodiazepines/Z-drugs

After Administration:

• Ensure patient is in bed with side rails raised before administering
• Monitor for respiratory depression (especially benzodiazepines + opioids or alcohol)
• Morning orientation assessment — residual sedation and cognitive impairment

Patient Education:

• Take only when planning 7–8 hours of uninterrupted sleep
• Do not operate motor vehicles or machinery until fully awake
• Avoid alcohol — potentiates CNS depression and significantly increases risk
• Do not take with high-fat meals (Z-drugs, ramelteon — delays absorption)
• Z-drugs: discontinue and report any episodes of sleep behaviors (sleepwalking, etc.)
• Benzodiazepines: do not stop abruptly; taper per provider instructions
• Emphasize intermittent use to prevent tolerance and maintain effectiveness

Related Concepts

• anxiolytics — Benzodiazepines used for both anxiety and insomnia
• sleep-support-measures — Nursing assessment and nonpharmacologic interventions for sleep
• psychotropic-medications — Overview of all psychiatric drug classes
• antidepressants — Trazodone (SARI) commonly used off-label as sedative for insomnia
• opioids — Combined opioid + benzodiazepine use dramatically increases respiratory depression risk
• geriatric-assessment-and-polypharmacy-safety — Beers Criteria and sedative-hypnotics in older adults

Self-Check

1. A 78-year-old patient requests a prescription for zolpidem. What concern would you raise with the provider, and what alternative might be appropriate?
2. A patient taking zolpidem reports waking up and finding food wrappers with no memory of eating. What is this phenomenon and what is the priority nursing action?
3. Why must benzodiazepines be tapered rather than stopped abruptly? What withdrawal complications can occur?